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Abstract: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and severe side-effect
in colorectal cancer (CRC) patients. This study assessed the association between habitual dietary
intake of magnesium or calcium and prevalence and severity of chronic CIPN in CRC patients
receiving adjuvant chemotherapy. For this prospective cohort study, 196 CRC patients were
considered. Magnesium and calcium intake was determined using a food frequency questionnaire at
diagnosis, during and after chemotherapy. Chronic CIPN was assessed 12 months after diagnosis
using the quality of life questionnaire CIPN20. Prevalence ratios were calculated to assess the
association between magnesium or calcium intake and the prevalence of CIPN. Multivariable linear
regression analysis was used to assess the association between magnesium or calcium intake and
severity of CIPN. CIPN was reported by 160 (82%) patients. Magnesium intake during chemotherapy
was statistically significantly associated with lower prevalence of CIPN (prevalence ratio (PR) 0.53,
95% confidence interval (CI) 0.32, 0.92). Furthermore, higher dietary intake of magnesium during (β
−1.08, 95% CI −1.95, −0.22) and after chemotherapy (β −0.93, 95% CI −1.81, −0.06) was associated
with less severe CIPN. No associations were found for calcium intake and the prevalence and severity
of CIPN. To conclude, we observed an association between higher dietary magnesium intake and
lower prevalence and severity of CIPN in CRC patients.
Keywords: calcium; chemotherapy; colorectal cancer; magnesium; neuropathy; oxaliplatin
1. Introduction
Chemotherapy-induced peripheral neuropathy (CIPN) is a common side-effect in colorectal
cancer (CRC) patients treated with oxaliplatin [1]. Oxaliplatin can cause both acute and chronic CIPN.
Symptoms of chronic CIPN include distal paresthesia, tingling sensations and numbness. Chronic
CIPN predominantly affects sensory nerves and can lead to long-term disability [1]. Occurrence and
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severity of chronic CIPN are related to the cumulative dose and dose-intensity of the treatment [1–3].
Six to eight months after the end of oxaliplatin treatment, 40–60% of the patients still suffer from
CIPN [4–7]. In order to minimize the detrimental effects in CRC patients, it is important to understand
which factors can influence the development and severity of CIPN.
Magnesium and calcium are proposed to be important in the etiology of CIPN, because they are
both involved in electric excitability of neurons and muscle contraction [8]. Low circulating levels
of magnesium, but not calcium, before treatment have been associated with more severe CIPN in
CRC patients [3]. Besides circulating levels of magnesium and calcium, several studies focused on
intravenous administration of magnesium and calcium and the severity of CIPN [9–16]. The clinical
observational study of Gamelin et al. found a lower occurrence and severity of CIPN in CRC patients
who received magnesium and calcium in comparison to patients who did not receive magnesium and
calcium for several reasons [9]. Other observational studies in CRC patients did not find an association
between intravenous magnesium and calcium infusions and CIPN [10,11].
Several randomized-controlled trials (RCTs) [11–15] studied the effect of intravenous magnesium
and calcium infusions on CIPN, but results are inconclusive. Grothey et al. reported a protective
effect of magnesium and calcium on the prevalence of CIPN in 102 colon cancer patients [12]. The
prevalence of CIPN was 22% in the magnesium and calcium group compared to 41% in the placebo
group (p = 0.04) [12]. On the contrary, four other RCTs conducted among 27–353 CRC patients, did not
find a protective effect of magnesium and calcium infusions on CIPN [13–16]. So far, no consensus
about the use of magnesium and calcium infusions to reduce or prevent CIPN has been reached [17].
Most studies conducted so far focused on acute CIPN during and directly after treatment. It
has been shown that further progression of CIPN can occur months after the end of treatment [1].
Moreover, the associations between dietary magnesium or calcium intake and the prevalence and
severity of chronic CIPN have not been described so far. Dietary intake in relation to CIPN is important
as dietary magnesium intake is the main contributor to the magnesium status. Further insights
into the relation between diet and CIPN may provide feasible opportunities for dietary strategies
directed against CIPN in cancer patients. In this prospective cohort study, we assessed the association
between habitual dietary intake of magnesium or calcium and the prevalence and severity of CIPN
approximately six months after chemotherapy, i.e., 12 months after diagnosis, in CRC patients receiving
adjuvant chemotherapy.
2. Materials and Methods
2.1. Patients
This study is embedded in the longitudinal observational study on nutritional and lifestyle factors
(COLON study), which is a prospective cohort study focusing on nutritional and lifestyle factors in
relation to clinical outcomes and quality of life of CRC patients in the Netherlands [18]. The design
and recruitment of the COLON study has been described in detail previously [18]. In short, newly
diagnosed CRC patients were recruited directly after diagnosis in 12 hospitals in the Netherlands and
were followed up during and after treatment. Men and women of all ages, who were in any stage
of the disease were eligible for the study. Non-Dutch speaking patients, or patients with a history of
CRC or (partial) bowel resection, chronic inflammatory bowel disease, hereditary CRC syndromes
(e.g., Lynch syndrome, Familial Adenomatous Polyposis, Peutz-Jegher), dementia or another mental
condition that made it impossible to fill out a questionnaire correctly, were excluded from the study.
Participants of the COLON study who were included between April 2012 and December 2015 and
who received adjuvant chemotherapy were eligible for the current study (n = 293). Patients who also
received neoadjuvant chemotherapy (n = 8), who did not start with chemotherapy (n = 22), or did not
fill out the questionnaire on CIPN (n = 67) were excluded, resulting in a total of 196 newly diagnosed
CRC patients eligible for the current study (Figure 1). Hospital records and linkage with the Dutch
ColoRectal Audit (DCRA) [19] were used to obtain data regarding cancer type, cancer stage and type
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of chemotherapy. All patients provided written informed consent. All procedures followed were
in accordance with the ethical standards of the institution and the COLON study was approved by
the Committee on Research involving Human Subjects, region Arnhem-Nijmegen, the Netherlands
(file 2009-349).
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Figure 1. Flowchart representing patient selection for the current study. Colorectal cancer patients
participating in the longitudinal observational study on nutritional and lifestyle factors (the COLON
study) and who received adjuvant chemotherapy and filled out the quality of life questionnaire to
assess chemotherapy-induced peripheral neuropathy (QLQ-CIPN16) were included in the present
study. * Patients who were recruited before April 2012 were not included in this study, because the
QLQ-CIPN16 questionnaire was implemented from April 2012 onwards.
2.2. Magnesium and Calcium Intake
A 204-item semi-quantitative food frequency questionnaire (FFQ) developed by the Division
of Human Nutrition of Wageningen University and Research, the Netherlands, was used to assess
habitual intake of magnesium and calcium from the diet during the previous month. The magnesium
or calcium content of a product was determined based on data from the Dutch food composition table
of 2011 [20]. Dietary intake of magnesium and calcium was calculated for each food item based on
frequency of intake, number of portions and portion size, as well as the type of product (e.g., whole
grain bread or brown bread). The total amount of the nutrients consumed per day was calculated by
adding all items containing the respective nutrient. The dietary intake of magnesium and calcium was
adjusted for total energy intake using the residual method [21]. Dietary supplement use was assessed
by a dietary supplement questionnaire developed by the Division of Human Nutrition of Wageningen
University and Research [18]. Intake of magnesium and calcium from dietary supplements was not
considered for the current study, due to the relatively low number of supplement users and the
lack of details on exact dosages, frequency and compliance. However, we performed sensitivity
analyses excluding patients who reported use of dietary supplements containing magnesium or
calcium. The FFQs and dietary supplement questionnaires were filled out at diagnosis and six and
12 months after diagnosis. These three time points represent the usual dietary intake before surgery,
during chemotherapy and six months after chemotherapy, respectively.
2.3. Chemotherapy-Induced Peripheral Neuropathy
Prevalence and severity of chronic CIPN were assessed using the ‘European Organization for
Research and Treatment of Cancer Quality of Life Questionnaire to assess Chemotherapy Induced
Peripheral Neuropathy’ (EORTC QLQ-CIPN16). This is an abbreviated version of the QLQ-CIPN20 [22],
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which is used in the COLON study. This questionnaire was filled out 12 months after diagnosis,
representing approximately six months after the end of chemotherapy. The QLQ-CIPN16 consists
of 16 questions of which eight assessing sensory symptoms and eight assessing motor symptoms.
These questions were shown to be valid and reliable to assess patient-reported CIPN [22]. Patients
reported the degree to which they have experienced sensory and motor symptoms during the past
week using a 4-point Likert scale. Sensory and motor scale scores from the QLQ-CIPN16 ranged from
1–32. The scores of the QLQ-CIPN16 were linear transformed to a 0–100 scale. Based on mean scores of
CIPN in the general Dutch population, the presence of CIPN was defined as >3.6 for the total CIPN16
score, >3.2 for the sensory sub-score and >3.8 for the motor sub-score [23]. Furthermore, we have
evaluated severity of CIPN-related symptoms by specifically focusing on the CIPN scores, with higher
scores indicating more severe CIPN. Missing values were handled by the mean-person imputation
method [24], however, participants were excluded from analyses when more than two items in the
QLQ-CIPN16 were missing.
2.4. Data Analysis
To study the association between magnesium and calcium and the prevalence of CIPN, prevalence
ratios (PR) were calculated using a Cox proportional hazards regression model, with a fixed time
variable. PRs were used, since odds ratios tend to overestimate the size of the association when the
outcome is common [25]. Subsequently, among patients suffering from CIPN, the association between
magnesium or calcium intake and the severity of CIPN was assessed by using multivariable linear
regression analysis.
The Shapiro-Wilk test was used to determine whether data were normally distributed. Dietary
intake of magnesium, calcium, vitamin D, total energy, as well as CIPN scores were natural-log
transformed. To adjust for potential confounding, the models were adjusted for age, gender as well
as energy adjusted dietary calcium or magnesium and vitamin D intake. When a variable changed
the regression coefficient of the independent variable with 10% or more, the variable was considered
to be a confounder and was added as a covariate to the model. Self-reported magnesium or calcium
supplement use, diabetes mellitus, physical activity, smoking, as well as B vitamins and alcohol
intake did not influence the observed associations. There was a strong correlation between protein
and magnesium intake (r = 0.81), as well as between protein and calcium intake (r = 0.80), therefore
we did not adjust for protein intake in the final model. Sensitivity analyses were performed for
oxaliplatin-containing chemotherapy (OX), patients with colon cancer and non-supplement users.
Stratified analysis was done for age (<65 and ≥65 years of age) to assess possible age differences.
Statistical analyses were performed in SAS 9.4 (SAS Institute, Cary, NC, USA). Ninety-five percent
confidence intervals (95% CIs), not containing 1 for the Cox regression analyses and not containing 0
for the multivariable regression analyses, represent statistically significant associations [26].
3. Results
3.1. Patients Characteristics
In total, 196 CRC patients from 12 hospitals in the Netherlands were included in this study. The
majority of the patients started with OX (n = 166, 85%), while 23 (11%) patients received capecitabine
monotherapy (Table 1). In our study population, 160 patients (82%) reported CIPN 12 months after
diagnosis. Among these patients, both sensory as well as motor CIPN symptoms were commonly
reported (81% and 76%, respectively). Common sensory symptoms included tingling and numbness in
fingers and toes, whereas difficulty with manipulating small objects and opening jars or bottles were
commonly reported motor symptoms. The severity of sensory symptoms was higher than the severity
of motor symptoms (mean score 20.8 and 12.5, respectively).
The median intake of magnesium was 317 mg/day and for calcium this was 851 g/day. The
most important food sources of magnesium in our population were whole grain bread and nuts. Also,
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coffee, dairy products, dark chocolate, banana and legumes were common sources of magnesium.
For calcium the most important food source was dairy products, especially cheese, yoghurt and milk.
The intake of magnesium was below the estimated average requirement of 350 mg/day for men and
265 mg/day for women [27] in 48% of our study population at the time of diagnosis. During and after
chemotherapy, 65% and 57% of the patients had an intake below the estimated average requirement,
respectively. The intake of calcium was below the estimated average requirement of 800 mg/day
for man <70 years and 1000 mg/day for man >70 years and 1000 mg for women [28] in 58% of our
population at the time of diagnosis, 59% during treatment and 65% after treatment.
Table 1. Characteristics of colorectal cancer patients who received adjuvant chemotherapy by
prevalence of chemotherapy-induced peripheral chemotherapy (CIPN).
CIPN
Total Population n = 196 CIPN No n = 36 (18%) Yes 1 n = 160 (82%)
Gender, women 71 (36%) 12 (33%) 59 (37%)
Age (years) 64.0 (59.8–68.1) 65.4 (59.0–68.2) 63.7 (59.9–68.0)
Diabetes mellitus (yes) 2 15 (8%) 3 (8%) 12 (8%)
Physical activity (meeting norm) 3 143 (73%) 25 (69%) 118 (74%)
Tumor stage
Stage II 15 (8%) 2 (6%) 13 (8%)
Stage III 145 (74%) 28 (76%) 117 (73%)
Stage IV 21 (10%) 3 (9%) 18 (11%)
Missing 15 (8%) 3 (9%) 12 (8%)
Cancer site
Colon 181 (93%) 33 (92%) 148 (93%)
Rectum 14 (7%) 3 (8%) 11 (7%)
Missing 1 (0%) 0 (0%) 1 (0%)
Type of chemotherapy
Oxaliplatin-containing (OX) 166 (85%) 27 (75%) 139 (87%)
Capecitabine monotherapy 23 (12%) 9 (25%) 14 (9%)
Other 2 (1%) 0 (0%) 2 (1%)
Missing 5 (2%) 0 (0%) 5 (3%)
Dietary factors
Magnesium intake from diet (mg/day) 2,4 317 (261–383) 325 (261–396) 313 (261–380)
Use of magnesium supplements (yes) 36 (18%) 6 (17%) 30 (18%)
Calcium intake from diet (mg/day) 2,4 851 (621–1143) 789 (597–1155) 861 (631–1123)
Use of calcium supplements (yes) 35 (18%) 6 (17%) 29 (18%)
Vitamin D intake from diet (mg/day) 2,4 3.1 (2.4–4.1) 2.8 (2.2–3.7) 3.2 (2.4–4.2)
Total energy intake (kcal/day) 2,4 1893 (1534–2265) 1898 (1547–2230) 1893 (1534–2285)
CIPN 5
Total score 6 14.6 (6.3–26.4) 0.0 (0–2.1) 16.7 (10.4–29.2)
Sensory score 7 16.7 (4.2–37.5) 0.0 (0–0) 20.8 (12.5–37.5)
Motor score 8 8.3 (4.2–20.8) 0.0 (0–0) 12.5 (8.3–20.8)
Values presented are median (quartile 1–quartile 3) or number (percentage). 1 Cut-off point for CIPN total score: 3.6,
2 Assessed at diagnosis. 3 Meeting the Dutch physical activity guideline of 150 min per week of moderate intensive
exercise at baseline, 4 Intake is missing for two patients, 5 Assessed 12 months after diagnosis. 6 Data for one patient
missing. 7 Data for two patients missing. 8 Data for five patients missing.
3.2. Dietary Magnesium or Calcium Intake and CIPN
Dietary intake of magnesium during chemotherapy was associated with the prevalence of chronic
CIPN (PR 0.53, 95% CI 0.32, 0.90) (Table 2). Among patients suffering from CIPN, a higher dietary
intake of magnesium was associated with less severe symptoms of CIPN (β −1.08, 95% CI −1.95,
−0.22 for the intake during chemotherapy and β −0.93, 95% CI −1.81, −0.06 for the intake after
chemotherapy) (Table 3). Dietary intake of calcium was not associated with the prevalence (Table 2)
and severity (Table 3) of CIPN.
Sensitivity analyses including only patients receiving OX (n = 166) or only patients with colon
cancer (n = 181) or only non-supplement users (n = 160–171) showed similar results (Table 4).
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Table 2. Association between dietary magnesium or calcium intake and the prevalence of chronic chemotherapy-induced neuropathy in colorectal cancer patients
receiving adjuvant chemotherapy.
n/Events Prevalence Ratio (95% CI) Total Score CIPN16 1 n/Events Sensory Symptoms 1 n/Events Motor Symptoms 1
Magnesium intake
Crude model
At diagnosis 194/158 0.81 (0.51, 1.29) 194/157 0.98 (0.64, 1.52) 194/147 0.95 (0.54, 1.67)
During chemotherapy 192/156 0.57 (0.35, 0.92) 192/156 0.70 (0.44, 1.12) 192/145 0.59 (0.33, 1.05)
After chemotherapy 181/147 0.67 (0.43, 1.05) 181/146 0.86 (0.57, 1.31) 181/136 0.61 (0.36, 1.03)
Full model
At diagnosis 194/158 0.69 (0.42, 1.13) 194/157 0.84 (0.51, 1.39) 194/147 0.81 (0.43, 1.52)
During chemotherapy 192/156 0.53 (0.32, 0.90) 192/156 0.67 (0.40, 1.10) 192/145 0.57 (0.30, 1.09)
After chemotherapy 181/147 0.61 (0.37, 1.03) 181/146 0.84 (0.51, 1.37) 181/136 0.51 (0.28, 0.93)
Calcium intake
Crude model
At diagnosis 194/158 1.15 (0.93, 1.41) 194/157 1.20 (0.98, 1.46) 194/147 1.12 (0.89, 1.41)
During chemotherapy 192/156 0.97 (0.83, 1.13) 192/156 1.02 (0.87, 1.19) 192/145 0.89 (0.73, 1.09)
After Chemotherapy 181/147 1.03 (0.86, 1.23) 181/146 1.08 (0.90, 1.30) 181/136 0.96 (0.78, 1.17)
Full model
At diagnosis 194/158 1.21 (0.95, 1.56) 194/157 1.24 (0.97, 1.58) 194/147 1.15 (0.88, 1.50)
During chemotherapy 192/156 1.03 (0.86, 1.23) 192/156 1.06 (0.89, 1.28) 192/145 0.92 (0.73, 1.16)
After Chemotherapy 181/147 1.08 (0.89, 1.32) 181/146 1.10 (0.89, 1.35) 181/136 0.99 (0.79, 1.24)
Analyses were performed using a Cox proportional hazard regression model, with a fixed time variable. Crude models: energy-adjusted intake of magnesium or calcium. Full model
for magnesium was adjusted for, energy-adjusted dietary calcium and vitamin D intake as well as age and gender. Full model for calcium was adjusted for, energy-adjusted dietary
magnesium and vitamin D intake as well as age and gender. 1 CIPN was defined as a score >3.6 for the total CIPN16 score, >3.2 for the sensory sub-score and >3.8 for the motor sub-score.
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Table 3. Associations between dietary magnesium or calcium intake and severity of chronic chemotherapy-induced neuropathy in colorectal cancer patients receiving
adjuvant chemotherapy.
Beta (95% CI)
n Total Score CIPN16 n Sensory Symptoms n Motor Symptoms
Magnesium intake
Crude model
At diagnosis 158 −0.68 (−1.45, 0.08) 157 −1.09 (−1,90−0.27) 147 −0.45 (−1.33, 0.43)
During chemotherapy 156 −1.21 (−2.01,−0.41) 156 −1.43 (−2.30,−0.57) 145 −1.25 (−2.16,−0.35)
After chemotherapy 147 −0.81 (−1.59,−0.04) 146 −1.05 (−1.87,−0.22) 136 −0.64 (−1.48, 0.21)
Full model
At diagnosis 158 −0.65 (−1,52, 0.20) 157 −1.10 (−2.01,−0.18) 147 −0.36 (−1.36, 0.63)
During chemotherapy 156 −1.08 (−1.95,−0.22) 156 −1.24 (−2.17,−0.32) 145 −1.25 (−2.24,−0.27)
After chemotherapy 147 −0.93 (−1.81,−0.06) 146 −1.11 (−2.04,−0.19) 136 −0.76 (−1.73, 0.21)
Calcium intake
Crude model
At diagnosis 158 −0.20 (−0.55, 0.14) 157 −0.31 (−0.68, 0.06) 147 −0.19 (−0.56, 0.18)
During chemotherapy 156 −0.31 (−0.62, 0.00) 156 −0.39 (−0.74, −0.04) 145 −0.31 (−0.66, 0.04)
After chemotherapy 147 −0.19 (−0.55, 0.17) 146 −0.36 (−0.75, 0.03) 136 −0.04 (−0.42, 0.35)
Full model
At diagnosis 158 −0.05 (−0.45, 0.35) 157 0.03 (−0.40, 0.45) 147 −0.19 (−0.61, 0.23)
During chemotherapy 156 −0.16 (−0.51, 0.19) 156 −0.14 (−0.52, 0.23) 145 −0.19 (−0.57, 0.19)
After chemotherapy 147 −0.03 (−0.42, 0.35) 146 −0.10 (−0.52, 0.32) 136 0.01 (−0.40, 0.43)
Analyses were performed using multivariable linear regression analyses. Crude models: energy-adjusted intake of magnesium or calcium. Full model for magnesium was adjusted for
energy-adjusted dietary calcium and vitamin D intake as well as age and gender. Full model for calcium was adjusted for energy-adjusted dietary magnesium and vitamin D intake as well
as age and gender.
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Table 4. Sensitivity analyses for the associations between dietary magnesium or calcium intake and severity of chronic chemotherapy-induced neuropathy.
Beta (95% CI)
n Total Score CIPN16 n Sensory Symptoms n Motor Symptoms
Patients receiving oxaliplatin-containing chemotherapy
Magnesium
At diagnosis 137 −0.68 (−1.58, 0.22) 138 −1.01 (−1.97,−0.05) 126 −0.48 (−0.53, 0.57)
During chemotherapy 136 −0.90 (−1.80,−0.00) 137 −1.10 (−2.06,−0.14) 125 −1.28 (−2.33,−0.24)
After chemotherapy 132 −0.94 (−1.85,−0.02) 133 −1.10 (−2.07,−0.12) 121 −0.94 (−1.98, 0.10)
Calcium
At diagnosis 137 0.00 (−0.42, 0.42) 138 0.08 (−0.36, 0.53) 132 −0.19 (−0.63, 0.26)
During chemotherapy 136 −0.18 (−0.54; 0.18) 137 −0.11 (−0.51; 0.28) 125 −0.28 (−0.69; 0.13)
After chemotherapy 132 0.00 (−0.39, 0.41) 133 −0.06 (−0.49, 0.38) 121 0.01 (−0.43, 0.45)
Not supplement users
Magnesium
At diagnosis 128 −0.80 (−1.80, 0.20) 126 −0.99 (−2.08, 0.10) 119 −0.68 (−1.83, 0.48)
During chemotherapy 136 −1.24 (−2.21,−0.27) 134 −1.20 (−2.27,−0.13) 128 −1.81 (−2.90,−0.71)
After chemotherapy 129 −1.34 (−2.30,−0.37) 126 −1.29 (−2.37,−0.21) 119 −1.38 (−2.44,−0.32)
Calcium
At diagnosis 127 −0.06 (−0.50, 0.37) 127 0.06 (−0.41, 0.53) 119 −0.08 (−0.56, 0.38)
During chemotherapy 140 −0.12 (−0.48, 0.23) 138 −0.07 (−0.45, 0.32) 132 −0.20 (−0.60, 0.20)
After chemotherapy 127 −0.00 (−0.41, 0.42) 130 −0.09 (−0.54, 0.36) 119 0.09 (−0.35, 0.53)
Colon cancer patients
Magnesium
At diagnosis 146 −0.66 (−1.54, 0.22) 145 −1.11 (−2.04,−0.18) 135 −0.34 (−1.37, 0.68)
During chemotherapy 145 −1.13 (−2.03,−0.23) 145 −1.34 (−2.30,−0.38) 134 −1.30 (−2.33,−0.26)
After chemotherapy 139 −0.80 (−1.71, 0.11) 137 −0.98 (−1.95,−0.02) 128 −0.66 (−1.67, 0.36)
Calcium
At diagnosis 146 −0.00 (−0.42, 0.41) 145 0.07 (−0.37, 0.51) 135 −0.15 (−0.58, 0.28)
During chemotherapy 145 −0.11 (−0.48, 0.25) 145 −0.07 (−0.47, 0.35) 134 −0.16 (−0.57, 0.26)
After chemotherapy 139 −0.03 (−0.45, 0.39) 137 −0.11 (−0.56, 0.34) 128 0.04 (−0.41, 0.50)
Analyses were performed using multivariable linear regression analyses. Models for magnesium was adjusted for energy-adjusted dietary calcium and vitamin D intake as well as age and
gender. Models for calcium was adjusted for energy-adjusted dietary magnesium and vitamin D intake as well as age and gender.
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Stratified analyses for age showed statistically significant associations between magnesium intake
at all three time points and the severity of CIPN for patients aged 65 and older (n = 88), but not for
patients younger than 65 years (n = 108) (data not shown).
4. Discussion
The aim of this study was to assess the association between magnesium and calcium intake and
CIPN in a prospective cohort of CRC patients. Dietary intake of magnesium during chemotherapy was
associated with a lower prevalence of CIPN. A higher dietary intake of magnesium, but not calcium,
during and after chemotherapy was associated with a lower severity of total CIPN symptoms.
The prevalence of CIPN approximately six months after chemotherapy, i.e., 12 months after
diagnosis, was higher than expected (81%) in our study population consisting of 196 CRC patients
treated with adjuvant chemotherapy. Argyriou et al. reported a prevalence of 40% for CIPN in CRC
patients six to eight months after finalizing their treatment containing OX [1]. CIPN is related to
various risk factors, including treatment schedule, dose per course, cumulative dose, time of infusion
and pre-existing peripheral neuropathy [1]. These factors likely vary between studies and countries.
Furthermore, difference in the prevalence of CIPN may be explained by different methods to assess
CIPN. Most previous studies used criteria of the National Cancer Institute (NCI-CTCAE) or the total
neuropathy score (TNSc) to assess CIPN [4–7]. These methods are based on clinical examination, while
the QLQ-CIPN16 is a patient-reported assessment of CIPN. The use of the QLQ-CIPN16 is inherent to
the large-scale setting of the COLON cohort study. Recent studies compared several commonly used
methods to assess CIPN [29,30]. A high correlation was found for the NCI-CTCAE and the EORTC
QLQ-CIPN [29,30]. Furthermore, we did expect a high prevalence of sensory symptoms, and not
motor symptoms, since OX is mainly associated with chronic sensory CIPN [1,31]. Although motor
symptoms were also commonly reported in our study, it should be noted that the severity of motor
symptoms was relatively low in the present study (mean score 12.5 versus 20.8 for sensory symptoms).
In the present study, we found that a higher magnesium intake was associated with a lower
severity of chronic CIPN, whereas no association for calcium was found. Both magnesium and calcium
are involved in electric excitability of neurons and muscle contraction [8]. A potential explanation
for the association between magnesium and the severity of CIPN is the role of magnesium in the
neuromuscular system and nervous tissue conduction [32]. It has been supposed that CIPN is caused
by the stimulating effect of OX on neural excitability due to re-configuration of sodium channels
in the cell membrane [33]. Magnesium (and calcium) are hypothesized to decrease OX-induced
hyper-excitability [34,35], thereby limiting damage of neurons. In addition, magnesium specifically
plays a role in membrane integrity and stability [32].
In the present study, we focused for the first time on dietary intake of magnesium and calcium in
relation to CIPN. It should be noted that magnesium levels in blood are tightly regulated [36]. When
circulating levels of magnesium are low, other tissues such as bone and muscle provide magnesium to
restore circulating magnesium levels. With a low magnesium intake, body stores of magnesium could
be depleted, while circulating levels are still in the healthy range [3,37]. Among our study population,
65% of the patients had an intake below the estimated average requirement of 350 mg/day for men
and 265 mg/day for women [28] during chemotherapy. Hypothetically, especially patients with a low
intake of magnesium could benefit from additional intake of magnesium, as a higher intake could
restore depleted body stores of magnesium and thereby increases availability of magnesium in muscles
and nerves. Stratified analyses for age showed a stronger association in patients aged 65 years and
older. In this group the percentages of patients with a magnesium intake below the estimated average
requirement was higher compared to participants younger than 65. In addition, during chemotherapy
more participants had a magnesium intake below the estimated average requirement compared to
before and after chemotherapy. These results indicate that an optimal magnesium status throughout
treatment is important. Further studies are needed to confirm these findings and to determine the
clinical relevance of the reported association between magnesium and CIPN.
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The present study has some limitations. First, intake from dietary supplements was not considered
because of the relative limited number of supplement users. In addition detailed data on dosage,
frequency and compliance was lacking and supplement use was not consistent over the study duration.
Also, the mineral content of the drinking water was not considered. Magnesium and calcium from
drinking water contribute to the total magnesium and calcium intake. In the Netherlands, magnesium
and calcium content in the tap water ranges from 1.7–26.2 mg/L (1–8% of the total intake) and
15–157 mg/L (1–17% of the total intake), respectively [38]. Second, although we explored the possible
interaction between magnesium or calcium and many nutrients like B vitamins, calcium, vitamin D,
vitamin E and alcohol, we could not exclude the possibility that other nutrients or bioactive compounds
contributed to the observed effects. Third, the prevalence of pre-existing CIPN was not taken into
account. Pre-existing CIPN is a risk factor for developing chronic CIPN [1]. Diabetes mellitus is
an important cause of peripheral neuropathy [39]. However, in the present study, adjustment for
self-reported diabetes mellitus did not influence the observed associations. In addition, we have
not been able to take specific information on treatment-related factors, such as cumulative dose of
chemotherapy and use of specific medications that may have influenced magnesium status into
account. However, in the specific setting of studies focusing on long-term (chronic) toxicities, dose is
a complicated factor. Patients who received a low (cumulative) dose may have experienced severe
(acute) toxicities which have resulted in a dose reduction or premature discontinuation of therapy.
Because of severe toxicities, among which potentially CIPN, an increased risk of chronic CIPN on the
long-term may be expected. On the other hand, patients who completed their scheduled treatment,
and hence received a high (cumulative) dose, may also have an increased risk of CIPN because of
extensive exposure to the cytotoxic regimens. Furthermore, although information on clinical and
socio-demographic characteristics of patients who did not fill out the QLQ-CIPN16 (n = 67, 23%) was
available, it remains unknown why they did not fill out the questionnaires. It could be that these
patients suffered from CIPN symptoms in their hands, resulting in selection which theoretically could
decrease the validity of the present study. However, we do not expect that these non-responses had a
major impact on the results of our study as the overall response rate was high (77%). The sample size
of this study was relatively small (n = 196) and restricted to CRC patients and therefore we cannot
state yet if generalization of our results to other cancer patients or chemotherapeutic agents is justified.
Finally, we did not measure blood levels of magnesium and calcium. It should be noted, however,
that the specific objective of this study was to investigate the association between dietary intake of
magnesium and CIPN. Next to that, circulating levels are tightly regulated and not representative for
magnesium levels in muscles and bone [37].
The present study also has important strengths. First of all, this is the first prospective cohort study
which assessed the association between habitual dietary intake of magnesium or calcium and CIPN.
Our data extend and complement existing evidence regarding the association between magnesium,
calcium and neuropathy. Previous studies focusing on infusions with magnesium and calcium showed
inconsistent findings and relied on acute exposure, while we assessed habitual, long-term intake of
magnesium and calcium. In addition, previous studies focused on acute CIPN (during and directly
after chemotherapy), while we focused on chronic and persistent CIPN. Therefore, this study provides
an important contribution to the limited knowledge on chronic CIPN and its association with diet
before, during and after chemotherapy. Furthermore, in the present study we used the 16 items of the
QLQ-CIPN20 that are considered to be valid and reliable [22]. This approach resulted in a clinically
relevant estimation of the prevalence and severity of CIPN compared to the QLQ-CIPN20 [22]. Due
the availability of detailed data on diet and other clinical and lifestyle factors, we could adjust for the
most plausible confounders, although residual confounding can never be fully excluded.
5. Conclusions
The results of this study showed that a higher dietary magnesium intake was associated with
a lower prevalence and less severe CIPN symptoms among CRC patients who received adjuvant
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chemotherapy. Further studies are needed to confirm our findings and to provide a solid basis for
future recommendations directed towards the intake of magnesium before and during chemotherapy.
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